Wall Street Zen lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) from a strong-buy rating to a buy rating in a research note released on Saturday,Wall Street Zen reports.
AMRX has been the subject of several other research reports. Piper Sandler reiterated an “overweight” rating and set a $21.00 price target on shares of Amneal Pharmaceuticals in a report on Wednesday, November 4th. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 17th. UBS Group restated a “buy” rating on shares of Amneal Pharmaceuticals in a report on Thursday, October 1st. Zacks Research raised shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Amneal Pharmaceuticals from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $23.00.
Get Our Latest Stock Analysis on AMRX
Amneal Pharmaceuticals Stock Performance
Shares of AMRX opened at $21.23 on Friday. Amneal Pharmaceuticals has a 1 year low of $11.39 and a 1 year high of $22.07. The stock has a market capitalization of $6.78 billion, a PE ratio of 22.84, a PEG ratio of 2.47 and a beta of 1.24. The company has a debt-to-equity ratio of 5.61, a quick ratio of 1.24 and a current ratio of 1.87. The stock has a 50-day simple moving average of $19.79 and a 200-day simple moving average of $16.15.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.03. The firm had revenue of $862.68 million for the quarter. Amneal Pharmaceuticals had a net margin of 4.17% and a return on equity of 283.50%. On average, analysts predict that Amneal Pharmaceuticals will post 0.98 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Amneal Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Paralel Advisors LLC purchased a new stake in Amneal Pharmaceuticals in the second quarter valued at $3,217,000. Renaissance Technologies LLC boosted its stake in Amneal Pharmaceuticals by 1,586.8% in the first quarter. Renaissance Technologies LLC now owns 276,637 shares of the company’s stock valued at $3,439,000 after acquiring an additional 260,237 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Amneal Pharmaceuticals by 37.6% during the first quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock worth $2,576,000 after purchasing an additional 56,588 shares during the last quarter. Congress Asset Management Co. grew its holdings in shares of Amneal Pharmaceuticals by 94.7% during the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock worth $30,701,000 after purchasing an additional 741,577 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in shares of Amneal Pharmaceuticals by 26.3% during the first quarter. Sei Investments Co. now owns 706,681 shares of the company’s stock worth $8,784,000 after purchasing an additional 147,249 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals is a U.S.-based pharmaceutical company that develops, manufactures and markets generic and specialty medicines. Its products include a broad range of generic drugs, including complex formulations and injectable medicines, as well as branded therapies in areas such as neurology and endocrinology. The company also operates AvKARE, which distributes pharmaceuticals and medical products to government, institutional and commercial customers. Amneal serves customers in the United States and in international markets.
Further Reading
- Five stocks we like better than Amneal Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
